HJLI - Hancock Jaffe Laboratories, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2900
-0.0900 (-3.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.3800
Open2.3400
Bid1.9500 x 2900
Ask2.5500 x 2200
Day's Range2.2900 - 2.5500
52 Week Range1.3100 - 5.6400
Volume76,116
Avg. Volume164,948
Market Cap32.444M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.7470
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE11 days ago

    Hancock Jaffe Successfully Completes Four VenoValve Implantations for First-in-Human Study

    IRVINE, CA / ACCESSWIRE / April 11, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in four additional patients for its first-in-human study in Bogota, Colombia. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, "It is amazing to observe these surgeries, and then watch our patients get up and walk less than two hours after the procedure. The first phase of the first-in-human Colombian study will include 5 to 10 patients who suffer from severe, chronic venous insufficiency (CVI) of the deep vein system, a condition that occurs when the valves in the veins of the venous system of the leg are injured or destroyed, causing blood to flow backwards (reflux) and pool in the lower extremities, and resulting in increased venous pressure (venous hypertension).

  • ACCESSWIRElast month

    Hancock Jaffe Enrolls Four Additional Patients for First-in-Human VenoValve Study

    IRVINE, CA / ACCESSWIRE / March 21, 2019 / Hancock Jaffe Laboratories, Inc. (HJLI), a developer of medical devices that restore cardiac and vascular health, has enrolled four additional patients for its VenoValve first-in-human study in Bogota, Colombia. HJLI expects to implant VenoValves in the four additional patients by the end of April 2019. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, ''We continue to make progress with our VenoValve first-in-human study and are excited to get these implantations underway so that we can continue to receive the feedback and accumulate the data that we need for our U.S. pivotal trial.

  • ACCESSWIRElast month

    Hancock Jaffe Announces Successful Start to CoreoGraft Study at Texas Heart Institute

    IRVINE, CA / ACCESSWIRE / March 18, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced the successful start of its CoreoGraftÒ pre-clinical feasibility study at the Texas Heart Institute. Bypasses using the CoreoGraft have now been successfully completed in two test subjects. Following the surgeries, flow rates were excellent as measured with Transonic probes.

  • ACCESSWIRElast month

    These Four Healthcare Stocks Could Test March Highs

    Given that the success of the healthcare industry is dependent on companies meeting the demands of patients who simply want to live healthy lives, any company taking a patient-centric focus to their healthcare framework has seen impressive gains in the first few months of 2019. Investors looking for potential opportunities could benefit from keeping tabs on the healthcare industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Hancock Jaffe Laboratories Inc (HJLI), Kitov Pharmaceuticals Ltd (KTOV), and Auris Medical Holding AG (EARS) are 4 healthcare companies heating up on Thursday.

  • ACCESSWIRElast month

    Hancock Jaffe Completes $2.7 Million Private Placement of Common Stock

    IRVINE, CA / ACCESSWIRE / March 13, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has closed a private placement of 2,360,051 shares of its common stock for aggregate gross proceeds of approximately $2.7 million with various accredited investors, including participation by a member of HJLI's management. The company intends to use these proceeds to fund the continued development of its two lead products and for working capital and general corporate purposes. "In advance of key milestones including preliminary data for our VenoValve® first in-human study, and our CoreoGraft® feasibility study, we wanted to strengthen our balance sheet and extend our operational runway," said Robert Berman, Hancock Jaffe's Chief Executive Officer.

  • GlobeNewswire2 months ago

    Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced the successful start of its VenoValve® first-in-human study in Bogota, Colombia. The patient was walking the day after the surgery, the VenoValve appears to be functioning as it should, and the patient shows no early signs of thrombosis, reflux, or other adverse events. Robert Berman, Hancock Jaffe’s Chief Executive Officer stated, “We are so excited to get our VenoValve study underway and are thrilled that the first patient is doing so well.

  • GlobeNewswire3 months ago

    Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced its objectives for its upcoming CoreoGraft® study at the Texas Heart Institute. HJLI expects to provide an update after the first implantation. Provided that the study is successful, Hancock Jaffe would then seek a Pre-FDA meeting to discuss the additional pre-clinical testing that will be necessary for in-human trials.

  • GlobeNewswire3 months ago

    Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced that Dr. Marc H. Glickman, HJLI's Chief Medical Officer, will be presenting at the 6th Israeli Vascular Access Conference in Herzlia, Israel on January 16, 2019. "There are many factors involved in gaining regulatory approval and market acceptance for medical devices, including having key opinion leaders on board, and having practitioners validate the clinical need for your products," said Robert Berman, Hancock Jaffe’s CEO.

  • GlobeNewswire3 months ago

    Hancock Jaffe Announces End Points for First-in-Human VenoValve Study

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced end-points for its upcoming VenoValve first-in-human study in Bogota, Colombia. Endpoints for the study will include improvements in reflux time, as well as rVCSS, VAS and VEINES scores, three well known clinical measurements for venous disease.  Patients will be monitored at regular intervals during the study with the 90 day and 180 day results being of particular importance to the Company and the U.S. Food and Drug Administration (“FDA”). Knowledge gained from the Colombian study will be used to make any necessary design modifications to the VenoValves in preparation for the Company’s U.S. pivotal trial.

  • GlobeNewswire4 months ago

    Hancock Jaffe Receives Approval for First-in-Human VenoValve Study

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has received regulatory approval from INVIMA, the Colombian equivalent of the U.S. Food and Drug Administration, for its first-in-human trial for the VenoValve®.  INVIMA is the final regulatory approval needed to begin the first-in-human study in Bogota, Colombia. Hancock Jaffe will now make arrangements to export the VenoValves into Columbia and begin screening and enrolling patients for the study.  The company will next provide an update once initial patient enrollment is completed and dates are set for the first implantations. “The first quarter of 2019 will be monumental for our company as we begin the VenoValve study in Bogota, and the CoreoGraft study at the Texas Heart Institute,” said Robert Berman, Hancock Jaffe’s CEO.

  • GlobeNewswire5 months ago

    Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it will begin a feasibility study for its CoreoGraft bioprosthetic graft on January 29th at the Texas Heart Institute.  The pre-clinical study will involve a series of CoreoGraft implantations. HJLI expects to have preliminary results from the study immediately after the first implantations and final results from the study at the end of March, 2019.

  • GlobeNewswire5 months ago

    Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

    Robert Berman, Hancock Jaffe’s CEO stated, “Dr. Marc Glickman, our Senior Vice President and Chief Medical Officer, will travel to Bogota at the beginning of December to begin site initiation, and surgical training for implantation of the VenoValve. Patient enrollment will begin immediately after the application for the first-in-human trial is approved by INVIMA.

  • GlobeNewswire5 months ago

    Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

    IRVINE, Calif., Nov. 13, 2018 -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health,.

  • Simply Wall St.7 months ago

    What Investors Should Know About Hancock Jaffe Laboratories Inc’s (NASDAQ:HJLI) Financial Strength

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Hancock Jaffe Laboratories Inc (NASDAQ:HJLI), as the company does not have to adhere to strict debt covenants. However, it also Read More...